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INTRODUCTION
This study provides an overview of statistics and trends for commonly occurring cancer sites. Data from the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) Program database are used to estimate several cancer statistics, including median age at cancer diagnosis, incidence rates, death rates, lifetime risk of developing cancer, survival, and prevalence. Results are presented for these statistics as well as statistics on second or multiple cancers occurring among survivors previously diagnosed with cancer and estimates of the future national burden due to the changing age structure of the U.S. population.
Trends in population-based cancer rates may be studied by (a) using a comparison of aggregate data for discontinuous time intervals as a snapshot of the U.S. cancer burden or (b) examining yearly rates over a complete time range through modeling or more sophisticated analytical techniques to characterize national trends. Both approaches are used here, with a comparison of conclusions. Past trends in cancer incidence rates, coupled with shifts in the U.S. age structure, are described by changes in the median age of patients diagnosed, which is a summary statistic of age-specific incidence for the population at risk.
The risk of developing cancer during a person's lifetime and for a fixed period of time starting at selected ages comprises a strategic concept that can affect individual health behavior and medical management of patients undergoing routine clinical care. However, once diagnosed with cancer, prognosis is key with survival influenced by the type of cancer, the extent of disease, and treatment modalities. Improvements in detecting cancer at earlier stages and advances in treatment have yielded an increase in the population of living individuals ever diagnosed with cancer. In addition, with improved outcomes and greater life expectancy, there is an increasing need to consider the development of multiple primary cancers. Long-term high-quality population-based cancer registries such as SEER provide important information on individuals who develop more than one primary cancer during their lifetime.
Projections of the U.S. cancer burden are calculated for 2000 through 2050 and demonstrate that long-term shifts in the age composition of the population will lead to changes in the number of cancer cases diagnosed in various age groups, assuming there are no changes in cancer incidence rates. This growth in the number of future cancer cases affects demands placed on the U.S. health care delivery system.
MATERIALS AND METHODS
The statistics presented herein, with the exception of mortality, were obtained from data collected at populationbased registries that participate in NCI's SEER Program [1] . The SEER Program is the only comprehensive source of population-based data in the U.S. that includes stage of cancer at the time of diagnosis and follow-up of all patients for survival data. In addition, each registry collects data on patient demographics, primary tumor site and histology, and first course of treatment. Cancer cases are identified through records from hospitals, private laboratories, radiotherapy units, nursing homes, and other health service units in the registry's defined geographic area, as well as death certificates on which cancer is listed as a cause of death. Table 1 presents the central cancer registries that contribute data to the SEER Program, the diagnosis years of participation, the current population size (percentage) of the U.S. population included in SEER geographic regions, and the number of cancer cases diagnosed for 2003. By 1975, all SEER-9 registries were reporting data annually to NCI, and most recent reports for cancer trends are based on diagnosis years 1975-2003. Cancers are coded according to the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) [2] . Cases collected before 2001 were machine-converted to ICD-O-3 codes. Extent of disease was converted into the American Joint Committee on Cancer tumor, node, and metastasis staging categories [3] .
The incidence and death rates presented in this article are expressed as the number of new primary cancers and deaths, respectively, per 100,000 persons at risk per year. Numerators (cases) for incidence rates are derived from the SEER Program, and numerators for death rates are obtained from the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention [4] , which collects data from all state vital health reporting systems. For cancer sites that pertain to one sex only, the population at risk is the sex-specific population (e.g., females for ovarian cancer). Incidence and death rates are age-adjusted according to the 2000 U.S. standard population based on 5-year age groups [5] . Population estimates in the denominator for calculation of incidence and death rates are obtained from the U.S. Census Bureau [6] .
SEER incidence and U.S. mortality data are available through 2003 diagnoses and deaths, respectively. When SEER cases are reported to NCI in November of each year, data are approximately 98% complete for all cancer sites combined, although some cancer sites, such as melanoma, are less complete. Cancer registries continuously update their databases, and SEER uses statistical modeling to adjust the observed data for underestimation due to reporting delays estimated from the receipt of data files in subsequent years [7] . Incidence, mortality, and survival statistics are presented for four racial groups (white, black, Asian Pacific Islander, and American Indian/Alaska Native) and one ethnic group (Hispanic).
Trends over a given time interval are summarized with the annual percent change (APC) [5] . The APC is obtained by fitting a regression line through the logarithms of the rates for the given time period using weighted least squares. The slope of the line is tested for significant increases or decreases. In addition, the joinpoint regression model [8] is used to characterize changes in cancer rates over time. Each joinpoint denotes a statistically significant change in trend. For the joinpoint analysis, the overall significance level was set to p ϭ .05, and a maximum of three joinpoints and four line segments were allowed.
The SEER software package DevCan was used to calculate the lifetime risk of developing cancer based on agespecific cancer rates for 2001-2003 diagnoses [9 -12] from SEER-17 incidence cases. These rates are converted to the probabilities of developing cancer for a hypothetical population [5] .
Cancer survival is estimated in different ways, depending on the intended purpose. Relative survival is calculated by comparing observed survival with expected survival from a set of people with the same characteristics as the patient cohort with respect to age, race, sex, and calendar period [13] . Relative survival estimates the effect of the cancer being considered on survival in the absence of other causes of death. It is always larger than or equal to the observed survival.
Multiple primaries describe diagnosis of two or more independent primary reportable neoplasms [14] in an individual. The number of multiple primary cancers observed in the follow-up period after diagnosis of a first primary cancer was divided by the expected number of cancers to produce a standardized incidence ratio (SIR) [15] . The expected number was obtained by applying age-, sex-, and site-specific incidence rates by calendar year to personyears at risk for each respective cancer case. The analysis cohort included patients from SEER-9 areas who were diagnosed from 1973 through 2003 with 18 common cancers for men and women. Excluded from the analyses were all death certificate-only, autopsy, and individual cases with in situ disease as the first cancer diagnosis. Follow-up times, that is, person-years, were computed from 2 months after diagnosis to avoid counting simultaneous cancers and were censored at the time of death, date last known alive, or December 31, 2003, whichever came first.
The number of new cancer cases by sex for selected cancer sites is projected into the future using age-specific population projections, with a baseline assumption that cancer rates remain at their current level. Population estimates for single-year ages were obtained from the U.S. Census Bureau for the years 2000, 2010, 2020, 2030, 2040, and 2050 [16, 17] . The single-year age-and sex-specific estimated cancer counts were calculated using delay-adjusted incidence rates obtained by applying appropriate delay-adjustment ratios from SEER-9 to the SEER-17 data. Estimated single-year counts were then produced for each type of can- [5] . It differs from incidence in that it considers both newly diagnosed and previously diagnosed persons. Prevalence is a function of both the incidence of the disease and survival.
RESULTS
The American Cancer Society has estimated, based on SEER Program data and NCHS reported deaths, that approximately 1,399,790 people will be diagnosed with cancer and 564,830 will die of this disease in 2006 [18] . An estimated 14,357 new cases of childhood cancers and 2,394 deaths are expected among those under the age of 20. Although childhood cancers are relatively rare, cancer is the leading cause of death in this age group. Death rates for childhood cancer have declined by approximately 47% since 1975. Rates for childhood cancers vary greatly by age. Unlike adult cancers, pediatric and adolescent cancers often are best described by a combination of histological type and primary site [19] . For this reason, childhood cancers are not further discussed in detail here. Table 2 shows the distribution of median age at diagnosis for selected primary cancer sites by 5-year time periods from 1974 through 2003. Comparing the most recent 5-year period (1999 -2003) with the earliest period (1974 -1978) , median age at cancer diagnosis for all sites combined increased by 2 years. Of 44 individual cancer sites, 19 sites (43%) showed an increase in median age at diagnosis of more than 2 years, and five sites (11%) showed a decrease in median age at diagnosis of more than 2 years.
Mesotheliomas showed the largest increase in median age at diagnosis (11 years). Cancer of bones and joints, Hodgkin lymphoma, cancer of the lip, lung and bronchus, and melanoma of the skin showed an increase in median age at diagnosis of 5 or more years. The following cancers were diagnosed at especially young ages (median age of 38 or younger): cancers of the bones and joints, Hodgkin lymphoma, and cancer of the testis. For these cancers, median age at diagnosis increased by [3] [4] [5] [6] [7] [8] Age-adjusted incidence rates are shown in Table 3 for 20 cancer types by sex and selected discontinuous 5-year time periods from 1974 to 2003. The description of data in this table is supplemented with conclusions drawn from an examination of yearly data adjusted for reporting delay [7] using joinpoint regression models [8] . Figures 1A and 1B demonstrate the results of the joinpoint regression analysis (i.e., show the years in which rates changed significantly) for the top 10 cancer sites in men and in women. Each bar is divided into the portions of the interval 1975 through 2003 with a change in rates-intervals are color-coded, with red denoting periods with increasing trends, green for decreasing trends, and yellow for periods with stable trends. The significant APCs for each time period are shown within the bar or for the most recent period at the right border of the bar. Joinpoint analysis can be used to quantify changes in incidence rates for specific years, as well as calculate statistically significant trends in time. This method of analyzing the data shows a continuum of change, whereas comparisons of isolated time intervals do not always capture the nature of change over the intervening period. Table 3 shows an increase in the incidence of breast cancer from 1974 to 2003. A more detailed analysis ( Table 3 present an incomplete picture of the long-term breast cancer trend. Thus, caution should be applied when considering statistics using discontinuous fixed intervals for assessing long-term trends and identifying years in which a change in trends has occurred.
For all sites combined, age-adjusted cancer incidence rates among men increased dramatically until 1992, fell sharply during the next few years, and since 1995 have been (Fig. 1B) . The analysis for leukemia presented in Table 3 does not convey this longterm increase since adjustment for reporting delay is included in Figures 1A and 1B but not in Table 3 [20]. Delayadjusted incidence rates include estimates for cancers reported after the initial data collection period for a diagnosis year. Incidence of thyroid cancer began to increase sharply in women early in the 1980s (Table 3; Incidence rates are per 100,000 population and are age-adjusted to the 2000 U.S. standard million population by 5-year age groups. Abbreviations: IBD, intrahepatic bile duct; NOS, not otherwise specified; ONS, other nervous system. Source: National Cancer Institute's SEER Program (SEER-9 areas); data from the Atlanta registry were available for cases diagnosed from 1975 and later.
Incidence rates by race and ethnic group based on SEER-17 areas are displayed in supplemental online Table  A . Sites selected were the top cancers based on 2000 -2003 age-adjusted incidence rates for all races combined for the given sex group (male, female, combined). Blacks had the highest incidence rate (504.4 per 100,000) for men and women for all sites combined. Prostate cancer incidence was 258.3 per 100,000 for black men and 163.4 per 100,000 for white men. Incidence rates for men with cancers of the prostate, lung and bronchus, colon and rectum, and oral cavity and pharynx were higher for blacks, whereas cancers of the urinary bladder, melanoma of the skin, and nonHodgkin lymphoma had higher incidence rates for whites. American Indian/Alaska Native men had the highest incidence rate of kidney and renal pelvis cancer, at 20.9 per 100,000. Among women, incidence rates for cancers of the colon and rectum and of the pancreas were higher for blacks than whites. White women had the highest incidence rates for breast, lung and bronchus, corpus and uterus not otherwise specified (NOS), non-Hodgkin lymphoma, melanoma of the skin, ovary, and thyroid cancers.
Death rates by race and ethnicity are displayed in supplemental online Table B . The sites selected were the top cancers based on 2000 -2003 age-adjusted death rates for all races combined for the given sex group (male, female, combined). Blacks had the highest death rates for men and women for all sites combined. Death rates for cancers of the lung and bronchus, prostate, colon and rectum, pancreas, and esophagus in men were highest in blacks. Leukemia, non-Hodgkin lymphoma, and urinary bladder death rates were highest for whites. Asian Pacific Islanders had the highest mortality for liver and intrahepatic bile duct cancer for both men and women (data not shown). Among women, overall death rates for cancers of the lung and bronchus and ovary, and for non-Hodgkin lymphoma and leukemia, were higher in whites than blacks, whereas female mortality for cancers of the breast, colon and rectum, pancreas, and corpus and uterus NOS were higher in blacks than in whites. Table 4 displays the lifetime risk of developing cancer, assuming that a person is cancer-free at the starting age. Approximately 45% (one in two) men and 38% (one in three) women will be diagnosed with some form of invasive can- cer during their lifetime. For a person 45 years of age, the risk of developing cancer during the next 10 years is 1 in 24 (1 in 26 for men; 1 in 22 for women). One in six persons, aged 65 years, will be diagnosed with cancer by age 75 (one in five for men; one in eight for women). Men have a one in six risk of having prostate cancer during their lifetime, and one in eight women will develop breast cancer. The lifetime risk of developing lung and bronchus cancer is 1 in 12 for men and 1 in 16 for women. Childhood cancers are rare; the risk of a newborn child developing cancer by the age of 10 is 1 in 612. By 30 years of age, 1 in 134 persons will develop some form of cancer. Starting at 65 years of age, approximately 43% (one in two) men and 30% (one in three) women will develop cancer.
Five-year relative survival for selected sites is shown by stage at diagnosis, sex, and race in Table 5 . The overall 5-year relative survival for individuals diagnosed in 1996 -2002 from SEER-17 geographic areas was 89% for female breast, 65% for colon and rectum, and 16% for lung and bronchus. For prostate cancer, relative 5-year survival is 49% at stage IV, although at all stages it is 100%. This can happen because relative survival measures exceed mortality relative to the general population, calculated as a ratio of the observed and expected survival.
Eventually
Survival changes considerably depending on stage at diagnosis. The 5-year relative survival varies from 95% to 98% for patients diagnosed with stage I to stage IV cancer of the colon and rectum, from 59% to 62% for patients with There is a difference in survival between men and women diagnosed with lung cancer. For persons diagnosed with stage I lung cancer, there is a nine-percentage-point higher relative 5-year survival for women compared with men. The sex difference is smaller for later-stage lung cancer but persists for both white and black patients.
For most cancers, relative survival generally is higher for white than for black patients. For female breast cancer, 5-year relative survival for all stages combined is 90% in white women compared with 78% in black women, with the highest difference occurring in stage III disease (5-year relative survival is 62% in whites vs. 45% in blacks). Similarly, there is a 10-percentage-point difference between races for patients diagnosed at all stages combined of colon and rectum cancer. This survival difference between white and black patients is the greatest for stage I disease in men and stage II disease in women, with smaller differences within other stages. Prostate cancer clinical stage IV survival is five percentage points higher in white males than in black males. Tables 6, 7 , and 8 relate to multiple primary cancers. Each table shows 18 primary sites at which cancer first originated. Table 6 shows the number of patients diagnosed with a first primary cancer, the number and percentage of these patients who then develop multiple primaries (within 2 months and after 2 months of an initial diagnosis), median age at diagnosis based on first cancer, and the 5-year relative and observed survival for these individuals with a first cancer diagnosis. Urinary bladder is the initial (or index) primary cancer site with the highest percentage of individuals with multiple primary cancers (16%), followed by oral cavity and pharynx (15%) and corpus and uterus (11%). When compared to all other primaries, liver cancer showed the fewest multiple primary occurrences (only 1%). As expected, there is an association between the risk of developing subsequent cancers and patient survival, with the exception of thyroid cancer.
SIRs [15] are shown in Table 7 for males and in Table 8 [21] . For a first cancer of the corpus and uterus, the risk of multiple primaries of the bladder and other urinary organ diseases was elevated (SIR ϭ 1.41, p Ͻ .05). Incidence of thyroid cancer after prostate cancer diagnosis was noted in men (SIR ϭ 1.20, p Ͻ .05).
Projections of cancer incidence counts for 2000 -2050 are displayed in Table 9 , and the pattern of estimated total number of cancers for age groups is presented in Figure 2 . As baby boomers (persons born from 1946 to 1964) age and move into the 45-64-age bracket by 2010, more new cancers are expected in this age group if incidence rates remain the same or do not decrease. For example, the group of adults aged 45-64 in the male and female all sites combined category shows an increase from 32% in 2000 to 37% in 2010. A similar increase in this age group can be seen for all of the top cancer sites. By 2030, baby boomers will have aged to between 66 and 84 years, the high-risk age group for cancer. This population growth impact is seen in the increase in the number of cancer patients in the 65-84-year age group in the year 2030. This increase is consistent for all of the top cancer sites.
The estimate for the total U.S. population of the prevalence of individuals alive on January 1, 2003 who had a previous diagnosis of cancer at any time is about 10.5 million (Table 10 ). This estimate includes individuals who recently were diagnosed with cancer, those who have survived many years after diagnosis, those with active cancer, and those who are cancer-free. Cancer is more prevalent in women, with an estimated 5.8 million having had a diagnosis of cancer by 2003. Men over the age of 70 constitute more than half of all men diagnosed with cancer. More than a million women in the 50 -69-year age group and another million women over the age of 70 have been diagnosed with breast cancer. Approximately 95% of the population previously diagnosed with acute lymphocytic leukemia is under the age of 50. The prevalence of prostate cancer is higher in men over the age of 70: nearly 1.3 of the 1.9 million men previously diagnosed with prostate cancer are at least 70 years old.
DISCUSSION
This study presents current SEER data and discusses measures of cancer incidence, mortality, lifetime risk, survival, prevalence, multiple primaries, and future projections of the numbers of people expected to be diagnosed with cancer. The goal of the National Cancer Institute's SEER Program is to collect complete and accurate data on all cancers diagnosed among residents of geographic areas covered by SEER cancer registries, currently comprising 26% of the U.S. population. SEER data provide clinicians and researchers with the opportunity to explore cancer trends, identify changing patterns in the cancer burden across diverse U.S. populations, measure progress against cancer, and examine implications for cancer control in the context of associations with risk factors, prevention interventions, and the dissemination of advances in treatment. Unique features of the SEER Program provided by more than 30 years of high-quality data include the following: (a) near-universal completeness of cases, with at least 98% of all malignant and specific in situ cancers reported within 22 months of diagnosis; (b) a combination of passive and active approaches for follow-up of all patients to estimate survival and prognosis; (c) long-term, population-based national trends in incidence and survival by stage at diagnosis; (d) a mature database for examining the development of multiple primary malignancies; and (e) routine use of the data for research in cancer etiology, quality of care, and innovative statistical modeling. Cancer incidence rates and trends are examined here in three ways: median age at diagnosis over time; comparison of summary incidence rates for four separate 5-year intervals spanning the time over which SEER data have been collected; and analysis of yearly incidence rates through modeling (joinpoint) and the determination of statistically significant APCs for trend segments over time. Median age at diagnosis has shifted slightly between 1974 and 2003, showing a small increase in age at diagnosis of about 2 years for cancer at all sites combined. For cancers common in young adults less than 40 years of age (e.g., bones and joints, Hodgkin lymphoma, acute lymphocytic leukemia, testis, and thyroid), the median age at diagnosis for all five sites has increased from 1974 -1978 to 1999 -2003 by 2-8 years.
Incidence data are frequently compared between two time periods of several years each to obtain sufficient cases for estimating rates. Although this method allows many aspects of the data to be observed, it does not show the detail available in an examination of yearly incidence rates over www.TheOncologist.com time. When adjusted for reporting delays, the age-adjusted incidence rates in men, which are primarily influenced by the rapidly changing trends in the diagnosis of asymptomatic prostate cancer, have been stable since 1995. For women, however, incidence rates continue to rise, influenced largely by changes in trends for cancers of the breast and lung. Detailed examination of breast cancer incidence shows stable rates in the most recent time period (2001-2003) , preceded by a deceleration in the rate of increase since about 1987. Factors such as the reduction in use of hormone therapy among postmenopausal women that occurred following the 2002 publication of results from the Women's Health Initiative [22, 23] and population effects of screening practices with mammography [24] that may explain the recent stabilization and possible decline in breast cancer incidence rates are under investigation. Similarly, although incidence rates for female lung cancer are increasing, the rate of increase is slowing. Increases in the incidence rate for thyroid cancer in women are particularly notable, par- tially due to occurrence after diagnosis of other primary cancers [25] . Our study shows that women diagnosed with lung cancer have better survival than men, especially those diagnosed with local-stage disease. The reasons for this survival advantage have not been identified, but it is likely due to a variety of factors. A previous study [26] analyzing the SEER database suggests surgery was performed more frequently in women than in men with local-stage disease. Since surgery offers these patients the best chance of longterm survival, this difference in treatment may partially explain the superior survival observed in women. Other concomitant factors such as comorbidity can influence treatment decisions for surgery and adjuvant therapy. In ad- dition, men and women smokers differ in the histological types of lung cancer with which they are diagnosedwomen are more likely than men to develop adenocarcinoma [27] . This difference in histology may also influence survival. For patients with local disease, Fu et al. [26] reported a negative impact on survival with any histologic types (small cell, squamous cell, and large cell) other than adenocarcinoma after controlling for demographic, temporal, and treatment effects. Further study is needed to evaluate the biological basis and its impact on sex-specific survival differences in lung cancer patients. The risk of developing cancer is often expressed in terms of lifetime risk, that is, the risk of a newborn developing cancer prior to death. Lifetime risk is confusing to many and assumes current rates hold over a person's entire lifetime. Shorter risk estimates (e.g., 10 years) conditional on a specific age are often much more understandable and meaningful when communicating risk. Data on risk of developing cancer in future years for men and women at 45 and 65 years of age are likely to be more relevant to patient concerns as they reach ages with established recommendations for cancer screening, as well as to clinicians who provide patient counseling concerning cancer prevention and early detection. In general, the risk of developing cancer increases with age, and differences in short-term risk are more pronounced by age (e.g., at birth, midlife, or retirement) than for long-term risk estimates. The risk of developing invasive cancer is generally higher for men than for women, except for risk associated with cancers occurring during the ages of 20 -54 years when women have substantially higher cancer incidence rates than men [5] .
Relative survival provides a measure of the excess mortality associated with a cancer diagnosis. The first source of major variation in survival is the particular cancer site. Stage at diagnosis is another major prognostic factor, and the decrease of survival with more advanced disease points to the importance of screening and early detection. However, cancers where early detection is less common, such as liver and pancreatic cancers, are among those with dismal overall relative survival rates. For early-stage lung cancer, a major cancer trial is underway to test the effectiveness of screening with spiral computed tomography imaging to diagnose early-stage disease [28] .
In general, black patients have lower relative survival, independent of cancer site and stage at diagnosis. This health disparity may be partially due to variations in the prevalence of risk factors, the use of screening tests for early detection, access to health care services, and/or social and demographic factors [29] .
Improvements in cancer survival affect cancer prevalence. As cancer survival improves and more individuals live longer after diagnosis, the prevalent population increases in size. This has led to a greater focus on several areas, such as long-term cancer treatment effects and their complications, issues that come into play in medical follow-up care. In addition, occupational, behavioral, and quality-of-life aspects of cancer survivorship are being addressed [30] . Prevalence provides information on the im- www.TheOncologist.com pact of cancer on the health care system and documents the need for increased research on the needs of survivors.
The SEER Program is the sole source of U.S. population-based data to address issues associated with multiple primary cancers [31] , using established rules for collecting and reporting more than one tumor per person. The SEER rules exclude recurrences or tumors of the same histology reporting within 2 months, with exceptions for some tumors such as retinoblastoma, bilateral ovarian tumors, adenocarcinomas of the prostate, certain bladder tumors, and a few others that are reported at one time. Analyses of multiple primaries presented here are based on a total population of over 2 million cancer patients diagnosed with cancer between 1973 and 2003 in the SEER-9 database, yielding approximately 12 million person-years at risk. For some initial cancer sites, a large proportion of multiple primary cancers occur at the same cancer site or organ system as the initial primary. This may be due to exposure, risk factors, or genetic predisposition. A process referred to as "field cancerization" involves effects of carcinogenic exposures or genetic factors over areas of tissues or organs [32] . Statistically significant increased multiple primaries in the same cancer site are reported for oral cavity and pharynx, kidney and renal pelvis, colon and rectum, and melanoma in both sexes, as well as urinary bladder and breast in women. The oral cavity and pharynx site seems to be the most extreme case, with SIRs of 29.5 and 11.5 in women and men, respectively.
Data are presented for various cancer sites, along with the percentage of multiple primaries found among those surviving more than 2 months, in addition to relative and observed 5-year survival among the cohorts. In general, an initial cancer site with a high percentage of multiple primaries must have a relatively high observed survival. For head and neck and urinary tract cancers (including oral cavity and pharynx and urinary bladder, the sites with the highest percentages of multiple primary cancers in Table 6 ), recent studies have shown evidence of a possible spread of cells from a single clone to multiple sites [33, 34] . Factors involved in multiple primary cancers in separate sites may include the effects of risk factors such as tobacco and alcohol on multiple organs, infections and immunosuppression, genetic predisposition, and treatment effects [32] . Cancer of the thyroid is seen particularly frequently in these data with statistically increased SIRs associated with initial primary cancers of the oral cavity and pharynx, kidney and renal pelvis, melanoma, and prostate in men and of the kidney and renal pelvis, melanoma, and breast in women. As a shared environmental etiology is unlikely for some cancer pairs such as melanoma and thyroid cancer, a likely explanation at present for any relationship between these two tumor types continues to be increased medical surveillance [35] . Information on multiple primaries is important to clinicians and cancer patients during medical management following initial treatment as well as in efforts to minimize iatrogenic effects of cancer therapy identified through analyses of multiple primaries. Projections into the future (through 2050) of the number of cancer cases and percentage of cases in four age groups show the effects of the changing age structure of the U.S. population. In this projection, with the cancer incidence rates held constant to current rates, the percentage of cancer patients for all sites combined in the 65-84-year age group increases to a peak in the year 2030 and then drops, whereas the number and percentage of cancer patients in the oldest age group continually increases. The population 85 years and older is the fastest-growing age sector of cancer patients. Our analysis indicates that, assuming constant cancer incidence rates, the number of cancer patients is expected to more than double from 1.36 million in 2000 to almost 3.0 million in 2050, due to aging and the growing U.S. population. This projection illustrates how cancer counts in a given age range may increase even when the incidence rate remains unchanged, due to the age structure of the population.
Substantial progress is being made against cancer for many, but not all, cancer sites and among many population groups, but not with equal effectiveness. These advances, however, have implications for health services needs in the future. As the prevalent population grows and more individuals live longer after a diagnosis of cancer, their medical care needs change. It is increasingly important to examine long-term treatment effects and to be aware of issues of multiple primary cancers. The population of individuals being treated for cancer is also aging, and projections for U.S. population dynamics will continue to age through the next half century. Thus, the patient population may have increased comorbid conditions that will affect both treatment decisions and healthcare during survivorship. We look to the SEER Program data as a continued source of information to chart these changing patterns as well as other aspects of the U.S. national cancer burden [36, 37] .
